Revolution Medicines, Inc. (RVMD)
| Market Cap | 2.71B |
| Revenue (ttm) | 46.32M |
| Net Income (ttm) | -105.01M |
| Shares Out | 64.89M |
| EPS (ttm) | -21.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $40.77 |
| Previous Close | $40.02 |
| Change ($) | 0.75 |
| Change (%) | 1.87% |
| Day's Open | 39.58 |
| Day's Range | 39.00 - 41.47 |
| Day's Volume | 825,228 |
| 52-Week Range | 19.65 - 45.49 |
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines (NASDAQ: RVMD) shares are trading higher on Thursday after the company reported a third-quarter EPS loss of 42 cents, up from a loss of $6.08 year-over-year and sales $12....
Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination
Plenary Presentation at EORTC-NCI-AACR 3 2 nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profile s for RMC-4630 Combined with Cobime...
Study Findings Selected for Oral Presentation in Plenary Session at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Study Findings Selected for Oral Presentation in ...
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)
REDWOOD CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to in...
Company’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event Company’s Scientific Leadership to Deliver Presentations, Pa...
Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million
Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common...
REDWOOD CITY, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of ...
Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus Newly Discovered Natural Product and Designed Analogues Bind to Human Pr...
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit front...
Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Ev...
REDWOOD CITY, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit front...
Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors
Stocks are firing on all cylinders again and have clawed back most of their bear-market losses.
Company to Host R&D Update Conference Call Following AACR Meeting Company to Host R&D Update Conference Call Following AACR Meeting
Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million
Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug Findings Support Plans to Expand Clin...
Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630 Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630
Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations Netherlands Cancer Institute Intends to Sponsor and Conduct ...
Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable
Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.
The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusi...
Revolution Medicines Inc. (NASDAQ: RVMD) entered the market with a bang on Thursday.
Shares of Revolution Medicines Inc. , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a r...
About RVMD
Revolution Medicines, a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi f... [Read more...]
| Industry Biotechnology | IPO Date Feb 13, 2020 |
| CEO Mark Goldsmith | Employees 117 |
| Stock Exchange NASDAQ | Ticker Symbol RVMD |
Financial Performance
In 2019, RVMD's revenue was $50.04 million, an increase of 148.16% compared to the previous year's $20.17 million. Losses were -$47.66 million, 14.1% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is 46.25, which is an increase of 13.44% from the latest price.